Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
11 05 2022
Historique:
received: 15 07 2021
accepted: 28 04 2022
revised: 10 04 2022
entrez: 10 5 2022
pubmed: 11 5 2022
medline: 14 5 2022
Statut: epublish

Résumé

The family of hexokinases (HKs) catalyzes the first step of glycolysis, the ATP-dependent phosphorylation of glucose to glucose-6-phosphate. While HK1 and HK2 are ubiquitously expressed, the less well-studied HK3 is primarily expressed in hematopoietic cells and tissues and is highly upregulated during terminal differentiation of some acute myeloid leukemia (AML) cell line models. Here we show that expression of HK3 is predominantly originating from myeloid cells and that the upregulation of this glycolytic enzyme is not restricted to differentiation of leukemic cells but also occurs during ex vivo myeloid differentiation of healthy CD34

Identifiants

pubmed: 35538058
doi: 10.1038/s41419-022-04891-w
pii: 10.1038/s41419-022-04891-w
pmc: PMC9091226
doi:

Substances chimiques

Hexokinase EC 2.7.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

448

Informations de copyright

© 2022. The Author(s).

Références

Lancet. 2011 Jul 2;378(9785):31-40
pubmed: 21705069
J Nucl Med. 2009 Sep;50(9):1525-32
pubmed: 19690031
Cancer Lett. 1994 Jul 15;82(1):27-32
pubmed: 7518342
Blood. 2019 Oct 17;134(16):1298-1311
pubmed: 31416800
Biochem J. 1993 Oct 15;295 ( Pt 2):329-41
pubmed: 8240230
Autophagy. 2010 May;6(4):506-22
pubmed: 20505359
Cell Cycle. 2006 Nov 1;5(21):2421-4
pubmed: 17102629
ACS Chem Biol. 2018 Feb 16;13(2):467-474
pubmed: 28892606
J Exp Biol. 2003 Jun;206(Pt 12):2049-57
pubmed: 12756287
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Arch Biochem Biophys. 1988 Dec;267(2):803-10
pubmed: 3214181
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Arch Biochem Biophys. 1996 May 1;329(1):17-23
pubmed: 8619630
Oncotarget. 2014 Jul 15;5(13):4671-82
pubmed: 25015728
J Biol Chem. 2002 Mar 1;277(9):7610-8
pubmed: 11751859
Eur J Cell Biol. 2017 Dec;96(8):728-738
pubmed: 29100606
J Exp Med. 2011 Feb 14;208(2):313-26
pubmed: 21242296
J Biol Chem. 2001 Nov 16;276(46):43407-12
pubmed: 11557773
Eur J Biochem. 1994 Feb 1;219(3):713-25
pubmed: 8112322
Arch Biochem Biophys. 1997 Sep 1;345(1):111-25
pubmed: 9281318
Biochem Biophys Res Commun. 1964 Jul 1;16(4):347-52
pubmed: 5871820
Blood. 2012 May 24;119(21):4963-70
pubmed: 22498738
Mol Cancer Ther. 2008 Sep;7(9):2941-54
pubmed: 18790775
Cell Death Differ. 2005 Aug;12(8):1008-14
pubmed: 15947788
Antioxid Redox Signal. 2014 Oct 10;21(11):1605-19
pubmed: 24762207
Nature. 2016 Sep 8;537(7619):239-243
pubmed: 27525555
Matrix Biol Plus. 2021 May 12;11:100066
pubmed: 34435183
Oncogene. 2006 Mar 30;25(14):2030-9
pubmed: 16301995
Oncogene. 2008 Dec;27 Suppl 1:S41-52
pubmed: 19641506
J Biol Chem. 1993 Sep 15;268(26):19161-4
pubmed: 8366068
Cancer Cell. 2013 Aug 12;24(2):213-228
pubmed: 23911236
Mol Cell. 2008 May 23;30(4):415-25
pubmed: 18498746
Rev Physiol Biochem Pharmacol. 1995;126:65-198
pubmed: 7886381
Nature. 2003 Aug 21;424(6951):952-6
pubmed: 12931191
Cell Death Differ. 2001 Dec;8(12):1213-23
pubmed: 11753569
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Proc Natl Acad Sci U S A. 1965 Oct;54(4):1218-25
pubmed: 5219826
Arch Biochem Biophys. 1992 May 1;294(2):482-92
pubmed: 1567204
BMC Cancer. 2014 Jan 15;14:27
pubmed: 24428916
Sci Rep. 2016 Feb 05;6:20585
pubmed: 26848099
J Bioenerg Biomembr. 2008 Jun;40(3):171-82
pubmed: 18683036
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
PLoS One. 2010 Nov 03;5(11):e13823
pubmed: 21072205
Am J Cancer Res. 2015 Jan 15;5(2):714-25
pubmed: 25973309
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8
pubmed: 12518064
Biochim Biophys Acta. 2009 May;1787(5):553-60
pubmed: 19285479
Oncogene. 2006 Aug 7;25(34):4683-96
pubmed: 16892082
Cell Death Differ. 2013 Sep;20(9):1268-78
pubmed: 23852375
Cancer Biol Ther. 2008 Jul;7(7):1128-35
pubmed: 18535403
Diabetes. 2006 Jan;55(1):1-12
pubmed: 16380470
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Cell Death Differ. 2009 Sep;16(9):1248-55
pubmed: 19407828

Auteurs

Kristina Seiler (K)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

Magali Humbert (M)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.

Petra Minder (P)

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

Iris Mashimo (I)

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

Anna M Schläfli (AM)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.

Deborah Krauer (D)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.

Elena A Federzoni (EA)

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

Bich Vu (B)

Department of Biology, University of Fribourg, Fribourg, Switzerland.

James J Moresco (JJ)

Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA.

John R Yates (JR)

Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA.

Martin C Sadowski (MC)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.

Ramin Radpour (R)

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.

Thomas Kaufmann (T)

Institute of Pharmacology, University of Bern, Bern, Switzerland.

Jean-Emmanuel Sarry (JE)

Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, Toulouse, France.
Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Joern Dengjel (J)

Department of Biology, University of Fribourg, Fribourg, Switzerland.

Mario P Tschan (MP)

Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland. mario.tschan@pathology.unibe.ch.
Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. mario.tschan@pathology.unibe.ch.

Bruce E Torbett (BE)

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA. betorbet@uw.edu.
Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA, USA. betorbet@uw.edu.
Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA. betorbet@uw.edu.
Institute for Stem Cell and Regenerative Medicine, Seattle, WA, USA. betorbet@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH